Multivariate Cox proportional hazards regressions for progression-free survival
| . | Adjusted hazard ratio* . | 95% confidence interval . | P . |
|---|---|---|---|
| First landmark analysis at start of maintenance therapy, N = 366 | |||
| MRD | |||
| Negative/positive | 0.22 | 0.15-0.34 | <.001 |
| Treatment arm | |||
| Transplantation/RVD alone | 0.68 | 0.52-0.88 | .004 |
| Second landmark analysis after 12 mo of maintenance therapy, N = 239 | |||
| MRD | |||
| Negative/positive | 0.18 | 0.12-0.29 | <.001 |
| Treatment arm | |||
| Transplantation/RVD alone | 0.76 | 0.54-1.07 | .115 |
| Modified intent-to-treat population, N = 509 | |||
| MRD | |||
| Negative/positive | 0.19 | 0.13-0.26 | <.001 |
| Treatment arm | |||
| Transplantation/RVD alone | 0.76 | 0.62-0.94 | .01 |
| . | Adjusted hazard ratio* . | 95% confidence interval . | P . |
|---|---|---|---|
| First landmark analysis at start of maintenance therapy, N = 366 | |||
| MRD | |||
| Negative/positive | 0.22 | 0.15-0.34 | <.001 |
| Treatment arm | |||
| Transplantation/RVD alone | 0.68 | 0.52-0.88 | .004 |
| Second landmark analysis after 12 mo of maintenance therapy, N = 239 | |||
| MRD | |||
| Negative/positive | 0.18 | 0.12-0.29 | <.001 |
| Treatment arm | |||
| Transplantation/RVD alone | 0.76 | 0.54-1.07 | .115 |
| Modified intent-to-treat population, N = 509 | |||
| MRD | |||
| Negative/positive | 0.19 | 0.13-0.26 | <.001 |
| Treatment arm | |||
| Transplantation/RVD alone | 0.76 | 0.62-0.94 | .01 |
Hazard ratio were adjusted on ISS disease stage and cytogenetic risk profile.